BCL6, a protein best known for its role in immune cell development, has emerged as one of the more promising biomarkers for detecting endometriosis without surgery. When overexpressed in the uterine lining, BCL6 disrupts the normal response to progesterone and appears to interfere with embryo implantation. For people struggling with unexplained infertility or repeated IVF failure, an endometrial biopsy measuring BCL6 levels can flag hidden endometriosis that imaging and physical exams miss, and the accuracy is surprisingly high.
How BCL6 Disrupts the Endometrium
In a healthy uterus, progesterone transforms the endometrial lining each cycle into a receptive environment for a potential embryo. BCL6 interferes with that process. The protein forms a complex with another molecule called SIRT1, and together they bind to and silence the promoter of GLI1, a gene that sits at the heart of the progesterone signaling chain known as the Indian Hedgehog pathway.1PubMed Central. KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance When GLI1 is suppressed, the endometrium essentially stops “hearing” progesterone’s signal even though progesterone itself is circulating at normal levels. This state is commonly called progesterone resistance, and it is a hallmark of endometriosis.2Human Reproduction Update. BCL6, a key oncogene, in the placenta, pre-eclampsia and endometriosis
Progesterone resistance has cascading consequences. The lining fails to undergo proper decidualization, the remodeling process that makes it hospitable to an implanting embryo. Cells that should become receptive remain unresponsive, and the inflammatory milieu that endometriosis creates in the pelvis compounds the problem. The result is an endometrium that looks normal on ultrasound but is functionally inhospitable. This is why many people with endometriosis-related infertility have no obvious anatomical explanation for their inability to conceive: the dysfunction is molecular, not structural.
BCL6 overexpression also appears to connect with broader disruptions in cell regulation. Research on the FOXO1 pathway, which normally governs decidualization and cellular turnover in the endometrium, shows that sustained activation of the same SIRT1 pathway that partners with BCL6 drives FOXO1 out of the cell nucleus, reducing its ability to promote the changes needed for implantation.3PubMed Central. Molecular Regulation of FOXO1 and Its Pathophysiological Significance in Endometriosis: A Narrative Review In other words, BCL6 isn’t acting alone. It’s part of a network of molecular signals that collectively push the endometrium toward a state that resists pregnancy.
BCL6 as a Diagnostic Biomarker
The gold standard for diagnosing endometriosis has traditionally been laparoscopic surgery, where a surgeon looks inside the pelvis and biopsies any suspicious tissue. That’s an invasive procedure with real costs and risks, and it leaves a gap for people who aren’t yet at a point where surgery makes sense. BCL6 testing fills part of that gap. A timed endometrial biopsy, taken during the secretory phase of the menstrual cycle, is stained and scored for BCL6 protein expression. The score, known as an HSCORE, quantifies how much BCL6 is present.
The diagnostic performance has been striking in initial studies. In a comparison of endometriosis patients and fertile controls confirmed by laparoscopy, BCL6 expression during the secretory phase distinguished the two groups with an area under the curve of 94%. Using an HSCORE cutoff of 1.4, the test was positive in 88% of people with unexplained infertility. When a subset of those patients went on to have laparoscopic evaluation, endometriosis was confirmed surgically in about 94% of them.4PubMed Central. Endometrial BCL6 Overexpression in Eutopic Endometrium of Women With Endometriosis A separate study in IVF patients found that BCL6 testing had a positive predictive value of 96% for endometriosis, and the few patients who tested positive but did not have endometriosis turned out to have other inflammatory pelvic conditions that were also treatable at the time of surgery.5PubMed Central. BCL-6 Overexpression as a Predictor for Endometriosis in Patients Undergoing In Vitro Fertilization
A more recent study of patients with unexplained infertility reinforced these numbers. Among 43 patients who underwent BCL6 screening before surgery, about 95% tested positive for BCL6 overexpression, and 100% were histopathologically confirmed to have endometriosis at surgery. Patients who had been screened with BCL6 testing beforehand also tended to have less advanced disease at the time of surgery compared to those who went straight to laparoscopy without screening, suggesting the test may help catch endometriosis at earlier stages.6PubMed Central. Noninvasive BCL6 Preoperative Screening and Anatomic Patterns of Endometriosis in Patients with Unexplained Infertility
These numbers make BCL6 one of the best-performing single biomarkers for endometriosis studied so far. That said, the evidence still comes from relatively small cohorts at specialized fertility centers, and there is no large-scale validation study with thousands of participants across diverse clinical settings. The test is commercially available under the name ReceptivaDx, but it is not yet considered a standard-of-care diagnostic in mainstream gynecology guidelines. Most of the clinicians ordering it work in reproductive endocrinology, particularly for patients with repeated IVF failure or unexplained infertility where something deeper is clearly going on.
What BCL6 Testing Means for IVF Outcomes
The clinical significance of BCL6 goes well beyond diagnosing endometriosis on paper. High BCL6 expression in the endometrium predicts meaningfully worse IVF outcomes. In a cohort study comparing IVF patients with normal versus elevated BCL6, people with low BCL6 had a clinical pregnancy rate of about 65%, while those with high BCL6 had a clinical pregnancy rate of roughly 17%. The gap in live birth rates was just as dramatic: about 59% for the low-BCL6 group versus roughly 12% for the high-BCL6 group.7PubMed Central. Endometrial BCL6 Testing for the Prediction of IVF Outcomes: a Cohort Study
These are large differences, the kind that can change the whole trajectory of someone’s fertility treatment. A live birth rate below 12% after embryo transfer is discouraging enough on its own, but what makes it worse is that many of these patients have no other obvious reason for failure. Their embryos look good, their hormone levels are adequate, their uterus appears normal on imaging. Without BCL6 testing, they and their doctors are left guessing why transfer after transfer fails.
This is also where the financial reality bites. Each IVF cycle can cost thousands of dollars, and repeated failures without a clear cause lead to emotional and financial exhaustion. A BCL6 test before embarking on another round of IVF offers a way to identify a treatable problem before spending more money on transfers that are unlikely to work. The test itself is a fraction of the cost of an IVF cycle, so even though it isn’t yet covered by most insurance plans, its potential to redirect treatment makes it a reasonable investment for many patients in the unexplained-infertility category.
Treatment After a Positive BCL6 Result
A positive BCL6 test isn’t just diagnostic. It opens the door to targeted treatment that can dramatically improve IVF success rates. The two main approaches are medical suppression of endometriosis, typically with GnRH agonists or similar hormonal medications that temporarily quiet the disease, and surgical excision of endometriosis via laparoscopy. Both have shown substantial benefit in patients with elevated BCL6.
In one study, patients with abnormal BCL6 expression who received either medical suppression or laparoscopic surgery before embryo transfer had a live birth rate of about 50-52%, compared to roughly 7% in those who went straight to transfer without treatment. The number needed to treat was three, meaning that for every three patients treated before embryo transfer, one additional live birth resulted that would not have happened otherwise.8PubMed Central. Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression That’s a substantial treatment effect by any standard in reproductive medicine.
The choice between medical suppression and surgery isn’t always straightforward. Medical suppression with a GnRH agonist is less invasive but temporary; the disease tends to return after treatment stops, so the window for embryo transfer is limited. Laparoscopic excision can remove visible endometriosis and potentially provide a longer-lasting benefit, but it carries surgical risks and requires an experienced surgeon skilled in identifying and excising often subtle disease. In practice, many reproductive endocrinologists make the decision based on the individual patient’s history, age, and preferences. Some patients end up doing both: surgery followed by a course of medical suppression before their next transfer.
What’s worth noting is that untreated high BCL6 predicted not only low implantation and live birth rates but also a high miscarriage rate. So even when embryos did implant in the untreated group, they were more likely to be lost. This suggests that BCL6-related progesterone resistance doesn’t just block implantation; it also undermines the endometrial environment needed to sustain an early pregnancy.
BCL6 and Recurrent Pregnancy Loss
The connection between BCL6 and miscarriage extends beyond IVF patients. In a study comparing people with unexplained recurrent pregnancy loss and those with unexplained infertility, BCL6 expression was elevated to a similar degree in both groups relative to fertile controls. About 79% of people in both the recurrent loss and the unexplained infertility groups had elevated BCL6 protein levels, and median HSCORE values were roughly tenfold higher in both subfertile groups compared to controls.9PubMed Central. Unexplained recurrent pregnancy loss and unexplained infertility: twins in disguise
This finding has important conceptual implications. It suggests that unexplained infertility and unexplained recurrent pregnancy loss may not be separate conditions but rather different presentations of the same underlying problem: an endometrium rendered dysfunctional by progesterone resistance driven by BCL6 overexpression, often rooted in undiagnosed endometriosis. Some people with this molecular environment fail to implant at all (presenting as infertility), while others implant but lose the pregnancy early (presenting as recurrent miscarriage). The common denominator is the same compromised endometrial environment.
This reframing matters for clinical decisions. People with recurrent pregnancy loss typically undergo a different workup than those with infertility, with testing focused on chromosomal abnormalities, uterine anatomy, blood clotting disorders, and hormonal imbalances. Endometriosis is often not considered early in the evaluation, especially if there are no classic symptoms like painful periods or pelvic pain. BCL6 testing could help identify a hidden endometriosis-driven cause in people whose recurrent losses remain unexplained after conventional testing. If the endometriosis is then treated before the next pregnancy attempt, the odds may improve substantially, as the IVF treatment data suggests.
How Frozen Embryo Transfer Protocols Influence BCL6 Levels
An unexpected wrinkle in the BCL6 story is that the protocol used to prepare the uterus for a frozen embryo transfer appears to influence BCL6 expression itself. In a study comparing three common approaches for frozen transfers, BCL6 levels varied dramatically. In natural cycles, where the body’s own hormones control the lining, the median HSCORE was 3.0 and about 80% of samples showed BCL6 overexpression. In modified natural cycles, which add a trigger shot and sometimes supplemental progesterone, the overexpression rate dropped to 40%. And in fully programmed cycles, where estrogen and progesterone are supplied externally and ovulation is suppressed, only about 23% of samples showed BCL6 overexpression.10Fertility and Sterility. B-cell lymphoma 6 expression significantly differs by the uterine preparation method used for frozen embryo transfer
After adjusting for other variables, the endometrium exposed to exogenous progesterone in programmed cycles had roughly 92% lower odds of BCL6 overexpression compared to a natural cycle. This is a striking effect, and it raises an important question: could the protocol chosen for frozen embryo transfer be partly masking or unmasking endometrial dysfunction? If you test BCL6 during a natural cycle, you see the underlying problem. If you test during a programmed cycle, you might miss it because the exogenous hormones are temporarily suppressing BCL6.
From a practical standpoint, this means the timing and context of BCL6 testing matters. A test done during a natural menstrual cycle is more likely to reflect the endometrium’s true baseline state. A test done during a medicated protocol might produce a falsely reassuring result. For clinicians ordering BCL6 testing, this distinction could be the difference between catching endometriosis-driven dysfunction and missing it entirely. It also raises the possibility that programmed frozen transfer cycles may partially compensate for BCL6-related progesterone resistance, which could explain some of the heterogeneity in IVF outcomes that has puzzled researchers.
The Limitations and Open Questions
For all its promise, BCL6 testing is not yet a settled part of endometriosis care. The studies supporting it, while showing strong diagnostic performance, are largely from a small number of research groups, and sample sizes remain modest. No multicenter randomized controlled trial has yet validated the approach across diverse populations and clinical settings. The commercial test, ReceptivaDx, is offered by a single company, and much of the foundational research was conducted by investigators associated with its development, which doesn’t invalidate the findings but is worth knowing when evaluating the evidence.
There are also questions about what BCL6 testing means outside the fertility context. Endometriosis affects an estimated one in ten people of reproductive age, and most of them are not trying to get pregnant at any given time. For someone with pelvic pain or other endometriosis symptoms who isn’t pursuing fertility treatment, the clinical utility of a BCL6 test is less clear. It may confirm a suspicion, but it doesn’t replace the need for laparoscopy in cases where treatment of visible disease is the goal. The test is most actionable when it changes a fertility treatment plan, specifically by prompting endometriosis treatment before embryo transfer.
Another open question is whether BCL6 levels change over time or with treatment in ways that are clinically useful for monitoring. If a patient has surgery for endometriosis, does BCL6 expression normalize afterward? And if it does, does that normalization correlate with better outcomes? These questions are being studied, but the answers aren’t definitive yet. For now, BCL6 testing is most useful as a one-time decision point: test before IVF, and if the result is abnormal, treat the endometriosis before proceeding.
Why Endometriosis Diagnosis Delays Still Happen
One reason BCL6 testing matters so much is the persistent problem of diagnostic delay in endometriosis. Studies across multiple countries consistently show an average delay of seven to ten years between the onset of symptoms and a surgical diagnosis. Part of this is because endometriosis symptoms overlap with many other conditions, but part of it is because the only definitive diagnosis has historically required surgery, and many clinicians are understandably reluctant to send patients to the operating room on suspicion alone.
Imaging has improved, and experienced sonographers can now identify deep infiltrating endometriosis and endometriomas on ultrasound. But superficial peritoneal endometriosis, which is the most common form and the type most often associated with infertility, remains largely invisible on imaging. This is exactly the gap BCL6 testing is positioned to fill. It detects endometrial dysfunction caused by the disease rather than the lesions themselves, so it can flag cases that ultrasound and MRI miss entirely. For the subset of patients whose primary concern is fertility, this approach offers a meaningful shortcut past the diagnostic limbo that has frustrated patients and clinicians for decades.11PubMed Central. Can we accurately diagnose endometriosis without a diagnostic laparoscopy?
The broader field of noninvasive endometriosis diagnosis is active, with researchers investigating blood-based biomarkers, salivary microRNA panels, and machine-learning approaches to imaging. None has yet reached the level of clinical validation needed for widespread adoption, and BCL6 remains among the furthest along in terms of demonstrated predictive value in a fertility setting. Whether it becomes a routine part of the infertility workup or remains a niche tool used by specialists will depend on larger validation studies, insurance coverage decisions, and how quickly the broader gynecology community integrates the molecular understanding of endometriosis into everyday practice.